Systemic adjuvant or neoadjuvant chemotherapy, biologic, and hormone therapies have improved outcomes of patients with early-stage breast cancer. However, a substantial number of patients with early-stage breast cancer still develop recurrent disease, and there is need of additional improvement of systemic therapies. Triple-negative breast cancer (TNBC) comprises approximately 15% to 20% of all…
PURPOSEThe standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase…
PURPOSEYoung age is associated with increased risk of recurrence in hormone receptor (HR)–positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is…
Surgical resection remains the most widely used curative approach for hepatocellular carcinoma (HCC), yet the postresection recurrence rate can be as high as 50%-70%. 1…
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on…
PURPOSEApproximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune…
PURPOSEThe objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor…
PURPOSEWe designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs.…
PURPOSETo assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs)…
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer…
PURPOSEOutcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I…
